Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Allogene Therapeutics Inc at Bank of America NAPA Healthcare Conference Transcript

Jun 15, 2021 / 06:30PM GMT
Release Date Price: $25.03 (-1.34%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

All right. Good day, everybody. Thank you for joining us at the BofA Biotech Summit. It's typically held in Napa. Unfortunately, we're in front of computer screens, but I think there's an end in sight that -- to a future that can be held with some red wine in the evenings. But gentlemen -- and I'm pleased -- I'm Jason Gerberry, biotech -- one of the biotech analysts at BofA. I'm pleased to be introducing Allogene CEO, David Chang; and CFO, Eric Schmidt. And gentlemen, thanks so much for joining us, first off.

Eric Thomas Schmidt
Allogene Therapeutics, Inc. - CFO

Thank you, Jason.

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Jason, thank you very much for having us. And as you say -- I mean today is June 15, so things are opening up. So pretty soon, hopefully, we will be back to normal.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot